#NEW from #CTAD2023 | Unraveling the #oligomer hypothesis in #Alzheimer’s disease 🎥 🧠 Eric Siemers MD, Acumen Pharmaceuticals, Inc., discusses the decades-long journey to understanding #Alzheimersdisease. Contrary to the longstanding #amyloid hypothesis, recent findings indicate that the soluble #oligomers of #amyloid-β (Aβ) are the toxic molecules, not the Aβ #monomers or #fibrils which constitute #plaques 💡Experiments reveal that these #globularoligomers disrupt long term potentiation, induce #intracellular #calcium influx, and lead to the #hyperphosphorylation of tau 💡The #oligomer hypothesis identifies these soluble oligomers as the key drivers of #Alzheimerspathology, positioning them as the best therapeutic targets 💡ACU193, is an investigation #monoclonalantibody that specifically targets these #oligomers. While the #FDA-approved antibody #lecanemab targets #protofibrils, which differ in shape from #oligomers but shares solubility and #toxicity, #ACU193 stands out as the sole #antibody capable of accurately testing the oligomer hypothesis Take a look 👉 https://lnkd.in/gWgJQ8ZT #Neurology
Excited to share that our Chief Medical Officer Eric Siemers MD had the opportunity to sit down with Video Journal of Dementia (VJDementia) to discuss all things #Alzheimers. In the first interview of a four-part series, Dr. Siemers explains how #Alz research has developed over the last 15 years and why #ACU193 was designed to selectively target amyloid beta oligomers (AβOs), which are a highly toxic form of Aβ. Watch here: https://lnkd.in/gWgJQ8ZT
